JP7332841B2 - 疼痛を治療するための薬用組成物 - Google Patents

疼痛を治療するための薬用組成物 Download PDF

Info

Publication number
JP7332841B2
JP7332841B2 JP2017100431A JP2017100431A JP7332841B2 JP 7332841 B2 JP7332841 B2 JP 7332841B2 JP 2017100431 A JP2017100431 A JP 2017100431A JP 2017100431 A JP2017100431 A JP 2017100431A JP 7332841 B2 JP7332841 B2 JP 7332841B2
Authority
JP
Japan
Prior art keywords
morphine
pain
mice
tolerance
opioid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017100431A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019052094A5 (https=
JP2019052094A (ja
Inventor
敏 卓
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Forever Cheer Holding Ltd
Original Assignee
Forever Cheer Holding Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forever Cheer Holding Ltd filed Critical Forever Cheer Holding Ltd
Priority to JP2017100431A priority Critical patent/JP7332841B2/ja
Priority to TW107116441A priority patent/TWI729290B/zh
Priority to IL259442A priority patent/IL259442A/en
Priority to AU2018203501A priority patent/AU2018203501B2/en
Priority to ES18000462T priority patent/ES2886855T3/es
Priority to DK18000462.4T priority patent/DK3403674T3/da
Priority to EP18000462.4A priority patent/EP3403674B1/en
Priority to KR1020180057362A priority patent/KR102096557B1/ko
Priority to CA3005375A priority patent/CA3005375C/en
Priority to ZA2018/03320A priority patent/ZA201803320B/en
Priority to CN201810482871.XA priority patent/CN108743589B/zh
Priority to US15/984,410 priority patent/US20180333420A1/en
Publication of JP2019052094A publication Critical patent/JP2019052094A/ja
Priority to US16/871,628 priority patent/US11541060B2/en
Publication of JP2019052094A5 publication Critical patent/JP2019052094A5/ja
Application granted granted Critical
Publication of JP7332841B2 publication Critical patent/JP7332841B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017100431A 2017-05-20 2017-05-20 疼痛を治療するための薬用組成物 Active JP7332841B2 (ja)

Priority Applications (13)

Application Number Priority Date Filing Date Title
JP2017100431A JP7332841B2 (ja) 2017-05-20 2017-05-20 疼痛を治療するための薬用組成物
TW107116441A TWI729290B (zh) 2017-05-20 2018-05-15 治療疼痛的藥物組合物
IL259442A IL259442A (en) 2017-05-20 2018-05-16 Medicinal preparations for the treatment of pain
ES18000462T ES2886855T3 (es) 2017-05-20 2018-05-17 Composiciones farmacéuticas para tratar el dolor
DK18000462.4T DK3403674T3 (da) 2017-05-20 2018-05-17 Farmaceutiske sammensætninger til behandling af smerte
EP18000462.4A EP3403674B1 (en) 2017-05-20 2018-05-17 Pharmaceutical compositions for treating pain
AU2018203501A AU2018203501B2 (en) 2017-05-20 2018-05-17 Pharmaceutical compositions for treating pain
CA3005375A CA3005375C (en) 2017-05-20 2018-05-18 Pharmaceutical compositions for treating pain
KR1020180057362A KR102096557B1 (ko) 2017-05-20 2018-05-18 통증 치료용 약학 조성물
ZA2018/03320A ZA201803320B (en) 2017-05-20 2018-05-18 Pharmaceutical compositions for treating pain
CN201810482871.XA CN108743589B (zh) 2017-05-20 2018-05-18 治疗疼痛的药物组合物
US15/984,410 US20180333420A1 (en) 2017-05-20 2018-05-20 Pharmaceutical compositions for treating pain
US16/871,628 US11541060B2 (en) 2017-05-20 2020-05-11 Pharmaceutical compositions for treating pain

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2017100431A JP7332841B2 (ja) 2017-05-20 2017-05-20 疼痛を治療するための薬用組成物

Publications (3)

Publication Number Publication Date
JP2019052094A JP2019052094A (ja) 2019-04-04
JP2019052094A5 JP2019052094A5 (https=) 2020-06-25
JP7332841B2 true JP7332841B2 (ja) 2023-08-24

Family

ID=62200214

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017100431A Active JP7332841B2 (ja) 2017-05-20 2017-05-20 疼痛を治療するための薬用組成物

Country Status (12)

Country Link
US (2) US20180333420A1 (https=)
EP (1) EP3403674B1 (https=)
JP (1) JP7332841B2 (https=)
KR (1) KR102096557B1 (https=)
CN (1) CN108743589B (https=)
AU (1) AU2018203501B2 (https=)
CA (1) CA3005375C (https=)
DK (1) DK3403674T3 (https=)
ES (1) ES2886855T3 (https=)
IL (1) IL259442A (https=)
TW (1) TWI729290B (https=)
ZA (1) ZA201803320B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114984020B (zh) * 2022-01-20 2024-08-30 永展控股有限公司 腺苷酸环化酶抑制剂在制备用于治疗癫痫及其相关疾病的药物中的用途
CN114931561B (zh) * 2022-05-25 2024-02-02 青岛永展医药科技有限公司 一种治疗慢性痛的胶囊组合物及其制备方法
CN115990167A (zh) * 2023-02-17 2023-04-21 永展控股有限公司 腺苷酸环化酶抑制剂nb001在制备治疗偏头痛和焦虑药物中的用途
CN115998745B (zh) * 2023-02-17 2024-05-14 永展控股有限公司 腺苷酸环化酶抑制剂nb001在制备治疗帕金森氏病疼痛和焦虑药物中的用途
CN118526502A (zh) * 2024-07-24 2024-08-23 浙江永展医药科技有限公司 腺苷酸环化酶抑制剂用于制备治疗围手术期疼痛药物的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009511508A (ja) 2005-10-14 2009-03-19 チュオ ミン 神経および非神経痛を治療する方法
US20110098295A1 (en) 2009-10-22 2011-04-28 Min Zhuo Methods of treating anxiety, itching and psychiatric disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6902336B2 (ja) * 2016-08-01 2021-07-14 永展国際有限公司Ｆｏｒｅｖｅｒ Ｃｈｅｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｌｉｍｉｔｅｄ ５−［２−［（６−アミノ）−９ｈ−プリン−９−イル］エチルアミノ］−１−ペンタノール多結晶体

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009511508A (ja) 2005-10-14 2009-03-19 チュオ ミン 神経および非神経痛を治療する方法
US20110098295A1 (en) 2009-10-22 2011-04-28 Min Zhuo Methods of treating anxiety, itching and psychiatric disorders

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Drug Discovery Today，2012年，Vol. 17, No. 11/12，pp. 573-582
MOLECULAR PAIN，2016年，Vol. 12，pp. 1-9
MOLECULAR PHARMACOLOGY，2006年，Vol. 70, No. 5，pp. 1742-1749
SCIENCE SIGNALING，2017年02月21日，Vol. 10，eaah5381, pp. 1-10，SUPPLEMENTARY MATERIALS

Also Published As

Publication number Publication date
AU2018203501A1 (en) 2018-12-06
JP2019052094A (ja) 2019-04-04
ES2886855T3 (es) 2021-12-21
TWI729290B (zh) 2021-06-01
US20180333420A1 (en) 2018-11-22
ZA201803320B (en) 2019-04-24
TW201900173A (zh) 2019-01-01
CA3005375C (en) 2020-12-08
IL259442A (en) 2018-06-28
KR20180127248A (ko) 2018-11-28
CA3005375A1 (en) 2018-11-20
EP3403674A1 (en) 2018-11-21
US20200268766A1 (en) 2020-08-27
US11541060B2 (en) 2023-01-03
DK3403674T3 (da) 2021-08-30
CN108743589B (zh) 2021-05-14
CN108743589A (zh) 2018-11-06
AU2018203501B2 (en) 2019-11-21
KR102096557B1 (ko) 2020-04-03
EP3403674B1 (en) 2021-06-30

Similar Documents

Publication Publication Date Title
JP7332841B2 (ja) 疼痛を治療するための薬用組成物
Leonard Serotonin receptors and their function in sleep, anxiety disorders and depression
Fan et al. Inhibition of calcium/calmodulin-dependent protein kinase II in rat hippocampus attenuates morphine tolerance and dependence
Gong et al. Supersensitization of the oral response to SKF 38393 in neonatal 6-OHDA-lesioned rats is mediated through a serotonin system.
JP2018008981A (ja) パーキンソン病におけるジスキネジアを治療するための新規ｄ３ドーパミン受容体アゴニスト
AU2002305809B2 (en) Treating pain by targeting hyperpolarization-activated, cyclic nucleotide-gated channels
TISSIER et al. Effects of ipsapirone, a 5‐HT1A agonist, on sleep/wakefulness cycles: probable post‐synaptic action
Dzoljic et al. 5-HT1-like receptor agonists enhance wakefulness
AU2002305738A1 (en) Treating neuropathic/inflammatory pain by targeting a composition (e.g.ZD7288) to HCN pacemaker channels
AU2002305809A1 (en) Treating pain by targeting hyperpolarization-activated, cyclic nucleotide-gated channels
Kasahara et al. The effects of AP521, a novel anxiolytic drug, in three anxiety models and on serotonergic neural transmission in rats
AU2013251426A1 (en) Compositions and methods for treating PTSD and related diseases
JP2024026905A (ja) てんかん治療剤
Bockaert et al. Localization of 5-HT4 receptors in vertebrate brain and their potential behavioral roles
Blaine Cellular and Behavioral Characterization of δ-Opioid Receptor Mediated ß-Arrestin Signaling
Blattner Design, synthesis and evaluation of 5-HT7 antagonists for the treatment of Inflammatory Bowel Disease
Tricklebank 5-HT Receptors
Grözinger et al. 18 Antihistamines and sleep
Ángel et al. Receptors in Learning
Deshpande Molecules in Epilepsy and Neuronal Excitability
Welsh The effect of serotonin 5-HT (2) receptor antagonists on classical conditioning of the rabbit nictitating membrane response
Risbrough CRF and serotonin 1A receptor influences on defensive startle behaviors
WO2008118403A2 (en) Method of using a pkc inhibitor to reverse prefrontal cortical declines

Legal Events

Date Code Title Description
AA31 Notification that no translation was submitted

Free format text: JAPANESE INTERMEDIATE CODE: A243631

Effective date: 20180925

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200515

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200515

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210330

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210630

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220316

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220316

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20220329

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220325

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220428

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220502

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220524

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20220525

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220524

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220530

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220530

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230706

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230719

R150 Certificate of patent or registration of utility model

Ref document number: 7332841

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150